Risk of developing Parkinson's disease among patients with asthma: A nationwide longitudinal study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 12, 2015, Pages 1605-1612

  Cheng, C M ^a   Wu, Y H ^a   Tsai, S J ^a,b   Bai, Y M ^a,b   Hsu, J W ^a,b   Huang, K L ^a,b   Su, T P ^a,b   Li, C T ^a,b   Tsai, C F ^a,b   Yang, A C ^a,b   Lin, W C ^a,b   Pan, T L ^c,d,e   Chang, W H ^a   Chen, T J ^a,b   Chen, M H ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

allergic diseases; asthma; Parkinson's disease; severity of asthma

Indexed keywords

ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; STEROID; XANTHINE DERIVATIVE;

ADULT; AGED; ALCOHOLISM; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CEREBROVASCULAR DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEAD INJURY; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANCE ABUSE; CROSS-SECTIONAL STUDY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; ASTHMA; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84983120189     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12758     Document Type: Article

References (33)

1. de Lau LM, Breteler MM,. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-535.
2. Lees AJ, Hardy J, Revesz T,. Parkinson's disease. Lancet 2009; 373: 2055-2066.
3. Rao G, Fisch L, Srinivasan S, D'Amico F, Okada T, Eaton C, et al., Does this patient have Parkinson disease? JAMA 2003; 289: 347-353.
4. Voelker R,. Parkinson disease guidelines aid diagnosis, management. JAMA 2006; 295: 2126-2128.
5. Chen MH, Li CT, Tsai CF, Lin WC, Chang WH, Chen TJ, et al., Risk of dementia among patients with asthma: a nationwide longitudinal study. J Am Med Dir Assoc 2014; 15: 763-767.
6. Perry VH,. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004; 18: 407-413.
7. Perry VH, Cunningham C, Holmes C,. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7: 161-167.
8. Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA,. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 2006; 67: 494-496.
9. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al., Attention deficit hyperactivity disorder, tic disorder, and allergy: is there a link? A nationwide population-based study. J Child Psychol Psychiatry 2013; 54: 545-551.
10. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al., Asthma and attention-deficit/hyperactivity disorder: a nationwide population-based prospective cohort study. J Child Psychol Psychiatry 2013; 54: 1208-1214.
11. Li CT, Bai YM, Huang YL, Chen YS, Chen TJ, Cheng JY, et al., Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 2012; 200: 45-51.
12. Shen CC, Tsai SJ, Perng CL, Kuo BI, Yang AC,. Risk of Parkinson disease after depression: a nationwide population-based study. Neurology 2013; 81: 1538-1544.
13. Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS,. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 2006; 4: 1-22.
14. Barbeau A,. Dopamine and disease. Can Med Assoc J 1970; 103: 824-832.
15. Hoffman NB, Laucka V,. Dexamethasone aerosol use in an asthmatic nursing-home patient with Parkinson's disease and dementia. DICP 1990; 24: 707-708.
16. Galli SJ, Tsai M, Piliponsky AM,. The development of allergic inflammation. Nature 2008; 454: 445-454.
17. Hirsch EC, Hunot S,. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-397.
18. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ,. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008; 131: 1880-1894.
19. Rincon M, Irvin CG,. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 2012; 8: 1281-1290.
20. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW,. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999; 100: 34-41.
21. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, et al., Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994; 180: 147-150.
22. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T,. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165: 208-210.
23. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, et al., Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun 2009; 23: 55-63.
24. Raison CL, Miller AH,. Do cytokines really sing the blues? Cerebrum 2013; 2013: 10.
25. Rosenkranz MA, Busse WW, Johnstone T, Swenson CA, Crisafi GM, Jackson MM, et al., Neural circuitry underlying the interaction between emotion and asthma symptom exacerbation. Proc Natl Acad Sci U S A 2005; 102: 13319-13324.
26. Yarlagadda A, Alfson E, Clayton AH,. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont) 2009; 6: 18-22.
27. Fernandez Pardal M, Fernandez Pardal J, Micheli F,. Aggravation of Parkinson's disease by cinnarizine. J Neurol Neurosurg Psychiatry, 1988; 51: 158-159.
28. Galhardo I, Coutinho MO, De Albuquerque ES, Medeiros Lde O,. Parkinson disease induced by flunarizine: report of a case. Arq Neuropsiquiatr 1993; 51: 546-548.
29. Anichtchik OV,. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp Neurol 2000; 163: 20-30.
30. Rocha SM, Pires J, Esteves M, Graca B, Bernardino L,. Histamine: a new immunomodulatory player in the neuron-glia crosstalk. Front Cell Neurosci 2014; 8: 120.
31. Shan L, Bossers K, Luchetti S, Balesar R, Lethbridge N, Chazot PL, et al., Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. Neurobiol Aging 2012; 33: 1488.
32. Aleyasin H, Rousseaux MW, Phillips M, Kim RH, Bland RJ, Callaghan S, et al., The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc Natl Acad Sci U S A 2007; 104: 18748-18753.
33. Papapetropoulos S, Ellul J, Argyriou AA, Talelli P, Chroni E, Papapetropoulos T,. The effect of vascular disease on late onset Parkinson's disease. Eur J Neurol 2004; 11: 231-235.